Viridian Therapeutics, Inc.

NasdaqCM VRDN

Viridian Therapeutics, Inc. Share Price on January 14, 2025: USD 16.86

Viridian Therapeutics, Inc. Share Price is USD 16.86 on January 14, 2025, a -23.74% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Viridian Therapeutics, Inc. 52-week high Share Price is USD 25.71 on November 11, 2024, which is 52.49% above the current Share Price.
Viridian Therapeutics, Inc. 52-week low Share Price is USD 11.60 on June 04, 2024, which is -31.20% below the current Share Price.
Viridian Therapeutics, Inc. average Share Price for the last 52 weeks is USD 17.70.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqCM: VRDN

Viridian Therapeutics, Inc.

CEO	Mr. Stephen F. Mahoney J.D., MBA
IPO Date	June 18, 2014
Location	United States
Headquarters	221 Crescent Street
Employees	94
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years